Immunome (IMNM) Equity Average (2023 - 2025)
Immunome (IMNM) has disclosed Equity Average for 3 consecutive years, with $449.1 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Average rose 126.79% year-over-year to $449.1 million, compared with a TTM value of $449.1 million through Dec 2025, up 126.79%, and an annual FY2025 reading of $407.8 million, up 170.89% over the prior year.
- Equity Average was $449.1 million for Q4 2025 at Immunome, up from $266.6 million in the prior quarter.
- Across five years, Equity Average topped out at $449.1 million in Q4 2025 and bottomed at $7.7 million in Q3 2023.
- Average Equity Average over 3 years is $203.2 million, with a median of $234.4 million recorded in 2024.
- The sharpest move saw Equity Average surged 2941.03% in 2024, then grew 6.86% in 2025.
- Year by year, Equity Average stood at $63.0 million in 2023, then surged by 214.45% to $198.0 million in 2024, then soared by 126.79% to $449.1 million in 2025.
- Business Quant data shows Equity Average for IMNM at $449.1 million in Q4 2025, $266.6 million in Q3 2025, and $288.2 million in Q2 2025.